Critical Care

Convalescent plasma is a transfusion of blood plasma from someone who has recovered from #COVID19, and is used as a treatment for COVID19 https://t.co/Bobq7OTDGq pic.twitter.com/pfO1sFvUpJ

— World Health Organization (WHO) (@WHO) December 7, 2021

RCT: In patients with severe Covid-19, high-flow oxygen therapy reduced the likelihood of invasive mechanical ventilation and decreased the time to clinical recovery compared to conventional oxygen therapy.

8 Dec, 2021 | 10:15h | UTC

Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial – JAMA

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation”.

[Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

Raising awareness for time-limited trial discussion upon ICU triage and admission.

8 Dec, 2021 | 09:57h | UTC

Raising awareness for time-limited trial discussion upon ICU triage and admission – Intensive Care Medicine (if the link is paywalled, try this one)

Commentary on Twitter

Enhancing situational awareness/prompt time-limited trial discussion vs burden/harm of inappropriate #ICU admission
F functional impairment
R recurrent hospitalisations
A advanced malignancy/chronic diseases
I irreversible organ failure
L long 🏥 stayhttps://t.co/C3aR2lbZtt pic.twitter.com/IB0xjSGVup

— Intensive Care Medicine (@yourICM) December 6, 2021

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

7 Dec, 2021 | 10:19h | UTC

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

News Release: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

7 Dec, 2021 | 10:23h | UTC

The Risk of Postoperative Complications following Major Elective Surgery in Active or Resolved COVID-19 in the United States – Annals of Surgery

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce.

7 Dec, 2021 | 10:12h | UTC

Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce – Medical Journal of Australia

IDSA Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.

7 Dec, 2021 | 08:49h | UTC

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections – Clinical Infectious Diseases

S2k guideline: diagnosis and treatment of carbon monoxide poisoning.

7 Dec, 2021 | 08:48h | UTC

S2k guideline diagnosis and treatment of carbon monoxide poisoning – German Medical Science

Clinical Review: Management of pneumonia in critically ill patients.

7 Dec, 2021 | 08:41h | UTC

Management of pneumonia in critically ill patients – The BMJ

Randomized clinical trials in critical care: past, present and future.

3 Dec, 2021 | 10:10h | UTC

Randomised clinical trials in critical care: past, present and future – Intensive Care Medicine

Commentary on Twitter

RCTs in critical care, history, major challenges & limitations, recent developments trying to solve some of these
📊conventional & novel RCTs
📊rationale for choosing methodological approach (advantages/potential disadvantages – pros/cons)@CritCareReviews https://t.co/kjCw7dFuou pic.twitter.com/xS9lHK4cuY

— Intensive Care Medicine (@yourICM) December 2, 2021

Retrospective Cohort Study: Except for Rituximab, most immunosuppressive medicines were not associated with increased risk of mechanical ventilation or death in patients hospitalized with Covid-19.

2 Dec, 2021 | 10:07h | UTC

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative – The Lancet Rheumatology

Commentaries:

What does endemic COVID-19 mean for the future of rituximab? – The Lancet Rheumatology

Outcomes for hospitalized COVID-19 patients taking immunosuppressive medications similar to non-immunosuppressed patients, study finds – Johns Hopkins University Bloomberg School of Public Health

Study: Immune-suppressed not at higher risk of poor COVID outcomes – CIDRAP

Commentary on Twitter

NEW RESEARCH—Long-term use of immunosuppressive medicines and in-hospital #COVID19 outcomes: data from N3C shows no increased risk of mechanical ventilation or in-hospital death with the exception of #rituximab https://t.co/vEyTzfvK5q #LancetRheumatology
@JohnsHopkins pic.twitter.com/NqlttjGrpj

— The Lancet Rheumatology (@TheLancetRheum) November 16, 2021

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

2 Dec, 2021 | 10:04h | UTC

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence – Drugs

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic.

1 Dec, 2021 | 09:52h | UTC

Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic – Critical Care

Another randomized trial showed convalescent plasma does not benefit patients hospitalized with Covid-19.

1 Dec, 2021 | 09:49h | UTC

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Network Open

M-A: Convalescent plasma does not reduce mortality in COVID-19.

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

Commentary on Twitter

The TSUNAMI RCT showed that high-titer convalescent plasma (CP) did not reduce the risk of severe respiratory failure or death in hospitalized patients with #COVID19 pneumonia. https://t.co/4q0S2AtfMj

— JAMA Network Open (@JAMANetworkOpen) November 29, 2021

M-A: Efficacy of non-invasive and invasive respiratory management strategies in adult patients with acute hypoxemic respiratory failure.

1 Dec, 2021 | 08:44h | UTC

Efficacy of non-invasive and invasive respiratory management strategies in adult patients with acute hypoxaemic respiratory failure: a systematic review and network meta-analysis – Critical Care

RCT: Small caliber 14-Fr percutaneous catheters (pigtail) were as effective as 28- to 32-Fr chest tubes in their ability to drain traumatic hemothorax with no difference in complications.

30 Nov, 2021 | 10:11h | UTC

The small (14 Fr) percutaneous catheter (P-CAT) versus large (28–32 Fr) open chest tube for traumatic hemothorax: A multicenter randomized clinical trial – Trauma and Acute Care Surgery (link to abstract – $ for full-text)

Stay Updated in Your Specialty